Article Details
Retrieved on: 2025-02-12 22:44:43
Tags for this article:
Click the tags to see associated articles and topics
Summary
Aethlon Medical Inc.'s Q3 2023 report highlights advancements in clinical trials targeting cancer and viral infections through the Hemopurifier, focusing on extracellular vesicles, with potential applications extending to organ transplantation, supported by strategic partnerships and financial improvements.
Article found on: www.tradingview.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here